← Back to Clinical Trials
Recruiting NCT06026345

NCT06026345 Affera Global Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06026345
Status Recruiting
Phase
Sponsor Medtronic Cardiac Ablation Solutions
Condition Atrial Fibrillation
Study Type OBSERVATIONAL
Enrollment 540 participants
Start Date 2023-12-22
Primary Completion 2028-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Affera Platform

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 540 participants in total. It began in 2023-12-22 with a primary completion date of 2028-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Affera Global Registry is a prospective, global, multi-center, observational post-market registry (PMR). The purpose of this study is to describe clinical performance and safety data in a broad patient population treated with the Affera Platform.

Eligibility Criteria

Inclusion Criteria: * Subject is ≥ 18 years of age or minimum age as required by local regulations * Planned procedure using the commercially available Affera Platform * Willing and able to comply with study requirements and give IC (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements Exclusion Criteria: * Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager * Subject with exclusion criteria required by local law

Contact & Investigator

Central Contact

Libby Bergmann

✉ libby.bergmann@medtronic.com

📞 libby.bergmann@medtronic.com

Frequently Asked Questions

Who can join the NCT06026345 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06026345 currently recruiting?

Yes, NCT06026345 is actively recruiting participants. Contact the research team at libby.bergmann@medtronic.com for enrollment information.

Where is the NCT06026345 trial being conducted?

This trial is being conducted at Brussels, Belgium, Prague, Czechia, Prague, Czechia, Bordeaux, France and 8 additional locations.

Who is sponsoring the NCT06026345 clinical trial?

NCT06026345 is sponsored by Medtronic Cardiac Ablation Solutions. The trial plans to enroll 540 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology